Compare Iamgold Corporation Ordinary Shares (IAG) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iamgold Corporation Ordinary Shares vs Repligen Corporation Common Stock — how do they compare? Iamgold Corporation Ordinary Shares trades at $17.22 (market cap $10.39B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Iamgold Corporation Ordinary Shares and Repligen Corporation Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Iamgold Corporation Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| IAG | RGEN | |
|---|---|---|
Market Cap | $10.39B | $11.14B |
Volume | 2,784,290 | 1,259,263 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $194.57 |
52-Week Low | $10.96 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.43B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAG trades at $18.27, down 1.62% today, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with a P/E of 9.23, net income margin of 31.4%, and ROE of 29.53%. Recent earnings show mixed results with two beats and one miss in the last three quarters. Analyst consensus is moderately bullish with a $22.00 price target, representing 20% upside potential from current levels.
IAG presents a compelling value opportunity with attractive valuation metrics and strong profitability. Key catalysts include Q3 2026 earnings release in November and operational optimization initiatives. Risks include commodity price volatility, execution challenges at mining operations, and potential cost pressures from rising fuel prices that could impact profitability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iamgold Corporation Ordinary Shares
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
